-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41

Benzinga·10/21/2026 13:12:02
Diffusion vocale
Truist Securities analyst Supawat Thongthip maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $40 to $41.